Immunitor CEO Joins Immune Network Board of Directors
14 Febbraio 2011 - 11:57AM
Immune Network Ltd. (Pink Sheets:IMMFF) is pleased to announce that
a co-founder of Immunitor, Dr. Aldar Bourinbaiar, has joined
Immune's board of directors. Immune Network is completing its
acquisition of 50% of Immunitor Inc., a company which has global
rights to a patented product called V5, clinically shown to be
effective against hepatitis B, hepatitis C, and recently
demonstrated as a potent immune adjunct for chemotherapeutic
management of tuberculosis, including drug resistant MDR-TB and
TB/HIV dual infection.
Immune Network's board of directors welcomes Dr. Aldar
Bourinbaiar, the principal and CEO of Immunitor. Dr. Bourinbaiar is
a doctor and a scientist (MD/PhD and PhD degrees from the
University of Paris, France), and a businessman with 30 years of
executive and operational experience combining basic science,
biotech industry, and patent law.He has worked at various academic
and business institutions in Mongolia, France, UK, Japan, Thailand
and USA, and speaks five languages. Dr. Bourinbaiar has spent four
years as an intellectual property advisor in leading law firms in
New York and Washington, DC and has substantial legal experience in
prosecuting patents and corporate law. He is inventor on eight US
patents and has published over 120 articles and chapters in books.
He is a member of the Editorial Board in several peer-reviewed
professional journals in vaccine and virology fields. He has been
involved in the biotech business since 1980 when he started working
on commercial blood products derivatives (gamma-globulin, albumin,
vaccines) at the Institute of Biochemistry of Blood in Mongolia. In
1987 he joined Hayashibara Biochemical Labs in Okayama, Japan – a
company that produces natural interferon and other important
biotech products for cancer and other indications. Dr. Bourinbaiar
is Thailand's regional representative elected by International
Organization on Biotechnology and Bioengineering, Stockholm,
Sweden. He is also an expert member of the Society of Industry
Leaders, a division of Standard & Poor's and consultant for
Reuters Insight, an independent research consultancy group owned by
Reuters. Dr. Bourinbaiar is listed in International Who is Who
Professionals, Marquis Who's Who, Marquis Who's Who in Asia, Who is
Who Historical Society, and Cambridge's 2000 Outstanding
Intellectuals of 21st Century.
Dr. Allen Bain, interim president, commented, "As we move ahead
with the corporate issues in Immune Network, the clinical
demonstration of V5 in several countries is continuing, thanks to
the global outreach work of Dr. Bourinbaiar and his associates. Dr.
Bourinbaiar's contribution to product registration and marketing
strategy will be essential to the growth of Immune Network and
implementation of V5 in the treatment of the millions of patients
worldwide who may benefit from its use."
Dr. Bourinbaiar joins Drs. Bain and Alexander Zolotoy on the
board of directors of Immune Network, and replaces outgoing
director Mr. Don Benard.
The Immune Network Ltd. logo is available at
http://www.globenewswire.com/newsroom/prs/?pkgid=8008
Safe Harbor Statement
The information in this release, other than historical
information, may be considered forward-looking statements within
the provisions of the Private Securities Litigation Reform Act of
1995. Projection and other forward-looking statements and
management expectations regarding future events and/or financial
performance of the Company -- although given in good faith -- are
inherently uncertain and actual events and/or results may differ
materially.
CONTACT: Immune Network Ltd
IMMFF@yahoo.com
Grafico Azioni Omni Bridgeway (PK) (USOTC:IMMFF)
Storico
Da Mag 2024 a Giu 2024
Grafico Azioni Omni Bridgeway (PK) (USOTC:IMMFF)
Storico
Da Giu 2023 a Giu 2024